Synaptogenix, Inc. (NASDAQ:SNPX) Short Interest Update

Synaptogenix, Inc. (NASDAQ:SNPXGet Free Report) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totalling 33,700 shares, an increase of 183.2% from the March 31st total of 11,900 shares. Based on an average daily trading volume, of 48,500 shares, the short-interest ratio is currently 0.7 days. Currently, 3.2% of the shares of the stock are sold short.

Synaptogenix Stock Up 2.7 %

Shares of NASDAQ SNPX traded up $0.12 on Friday, hitting $4.53. The company’s stock had a trading volume of 6,923 shares, compared to its average volume of 42,709. Synaptogenix has a 12-month low of $3.53 and a 12-month high of $47.00. The stock has a 50 day moving average of $4.79 and a 200-day moving average of $5.89.

About Synaptogenix

(Get Free Report)

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.

Read More

Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.